• Acura Pharmaceuticals filed a late notice for its Form 10-Q for quarter ended March 31, 2026, citing liquidity pressure and uncertainty over its ability to meet day-to-day operating obligations.
• Company said it is dependent on loans from Abuse Deterrent Pharma to fund operations, with no assurance that funding will continue or support longer-term needs.
• Registrant disclosed it has not filed annual reports for fiscal years 2022-2025 or any quarterly reports for 2022-2025, citing halted audit and review work tied to funding constraints.
• It has not engaged an independent registered public accounting firm for review or audit services for 2024-2026 results.
• Late notice said Form 10-Q is expected to be filed within the Rule 12b-25 extension window.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acura Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-059834), on May 13, 2026, and is solely responsible for the information contained therein.